March 18, 2015
On March 16, 2015, CMS solicited public comments regarding The National Oncology PET Registry’s (NOPR) request to end the prospective data collection requirements under coverage with evidence development (CED) for use of NaF-18 PET imaging in intended patient management. NOPR believes that the evidence-based conclusions from their analysis of the extensive NOPR NaF data set supports both the end the data collection requirement as well as the authorization for national coverage of NaF PET for bone metastasis for all oncologic indications.
Sodium Fluoride F-18 (NaF-18) is a radioisotope commonly used in oncologic PET imaging procedures to detect bone metastasis in cancer and is the focus of this national coverage analysis. The rate of NaF-18 uptake provides information on the tissues being studied. NaF-18 PET evaluation can indicate the probable presence or absence of bone metastasis based upon observed differences in biologic activity of adjacent tissues.
Public comments are due no later than April 15, 2015. Comments may be submitted here.
Keys to an effective CMS comment letter can be found here.